

# Microbiology Quality Assessment

**Elizabeth Bearr, Ph.D.**

Microbiology Reviewer

Office of Process and Facilities/Division of Microbiology Assessment

Office of Pharmaceutical Quality

CDER/FDA

Generic Drug Forum

April 12, 2018

# DMA Product Quality Microbiology

- Assessment of:
  - Manufacturing process
    - Sterility assurance supporting validation studies
  - Microbial process controls
    - Bioburden testing, filter integrity testing, environmental monitoring
  - Finished product quality attributes
    - Sterility, endotoxins, bioburden, container closure integrity, antimicrobial effectiveness

# Efficient Assessment

An assessor's job is to assess the information provided to them.

If an assessor has to search for or request information, the assessor becomes a detective and assessment efficiency might be impacted.



# Make it Easy to Understand

- Don't leave out the basics:
  - Equipment name/ID, filling line name, room numbers
  - Validation and production parameters and loads
  - Validation approach, e.g., production loads/parameters, worst case loads/parameters, bracketing





## Make it Logical

- Provide context in an introduction
  - Tell us how the validation supports commercial production
  - “Autoclave X was qualified by performing 3 empty chamber HD runs and 3 worst case HP/BI runs in 2016. The worst case load covers all loads proposed for production.”



# Make it Simple

- Summarize relevant results
  - Long reports containing hand-written notebook pages and unrelated validation studies
- vs.
- Summary tables with data for relevant loads:  
Min/max temperatures achieved, min/max  $F_0$ , BI results

# Drug Master Files

- Problems with DMFs may cause confusion and potentially impact assessment efficiency



# Drug Master Files

- Considerations:
  - Specify in LOA where ***relevant*** validation is (e.g., submission date, section and page numbers)
  - Electronic DMF submissions (May 5, 2018!)
  - Provide information directly in the marketing application




# Common Deficiency Topics

1. Validation of pre-sterilized equipment
2. Media Fill Process Simulation
3. Drug Product Endotoxins Testing
4. Extended Storage Times Following Reconstitution / Dilution

# Validation of pre-sterilized equipment

- Issue: Lack of sterilization validation for pre-sterilized, commercially available filling/filtration components (e.g. holding bags, filters)



# Validation of Pre-sterilized Equipment

- Consideration: Clearly mention the use of pre-sterilized equipment in the application
  - Clearly indicate party responsible for sterilization of the system
  - If you are sterilizing it, too, tell us!
  - Reference DMF or provide sterilization validation in application

# Validation of Pre-sterilized Equipment

- Why?
  - Avoid deficiencies concerning the content of equipment loads or which equipment is included in SIP validation
  - ‘Worst-case load’ isn’t descriptive enough

# Media Fill Process Simulation

- Issue: Comparison of media fill simulation conditions to production conditions missing
- Consideration: Describe how media fill conditions simulate production/worst-case process



# Media Fill Process Simulation

- Why?
  - Avoid simple deficiencies requesting:
    - Maximum filling duration
    - Filling speed
    - Routine/non-routine interventions
    - Container size/type

# Drug Product Endotoxins Testing

- Issue: Pooling samples results in additional dilution equal to the number of pooled samples should only one sample exceed the endotoxins limit
- Considerations:
  - Pooling acceptable
  - MVD adjusted to proportional lower value
  - ‘Adjusted MVD’ =  $MVD / \# \text{ of samples pooled}$

# Drug Product Endotoxins Testing

- Why?:
  - Ensure test method's ability to overcome potential product-related interference or enhancement







## Storage Post-Constitution / Post-Dilution

- Issue: Lack of microbiological studies in support of post-constitution / post-dilution storage time specified in package insert.
- Consideration: Provide risk assessment including microbiology challenge study data to support the post-penetration holding parameters to demonstrate that the final solution(s) do not support microbial growth during the storage period.

# Storage Post-Constitution / Post-Dilution



- Potential study design
  - Inoculate final drug solution with minimum countable inoculum ( $\leq 100$  CFU/mL) of challenge organisms
  - Incubate at specified storage temperature(s)
  - Sample at specified storage time(s) as well as intermediate and extended storage times
  - Growth generally accepted as population increases  $> 0.5 \log_{10}$

# Storage Post-Constitution / Post-Dilution

- Why?
  - Understand the risk associated with product labeling with regard to in-use stability and/or diluent compatibility claims



## Reach the Approval Finish Line!

- Make the information easy to understand, logical, and simple to assess
- Avoid common deficiencies for basic information



# Contact Information

Elizabeth Bearr, Ph.D.  
elizabeth.bearr@fda.hhs.gov

# Technical Questions

- How to submit Controlled Correspondence

<https://www.fda.gov/downloads/Drugs/GuidanceCompliance%20RegulatoryInformation/Guidances/UCM411478.pdf>

- Mail to: [GenericDrugs@FDA.HHS.Gov](mailto:GenericDrugs@FDA.HHS.Gov)

# References

- *Guidance for Industry for the Submission of Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products*  
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072171.pdf>
- *Guidance for Industry: ANDA Submissions – Refuse-to-Receive Standards – 2013*  
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM370352.pdf>

# References

- *Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice*

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070342.pdf>

- *Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers - 2012*

<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm314718.htm>



# References

- *Guidance for Industry: Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*

<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM333969.pdf>

